首页> Scandinavian journal of gastroenterology> Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.

Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anders,Forss

第一单位： Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

作者： Anders,Forss ^[1] ; Mark,Clements ^[1] ; Pär,Myrelid ^[2] ; Hans,Strid ^[3] ; Charlotte,Söderman ^[4] ; Agnieszka,Wagner ^[5] ; David,Andersson ^[6] ; Fredrik,Hjelm ^[7] ; PROSE SWIBREG study group ^[8] ; Ola,Olén ^[9] ; Jonas F,Ludvigsson ^[10] ; Jonas,Halfvarson

作者单位： Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ^[1] Department of Surgery, Linköping University Hospital, Linköping, Sweden.;Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. ^[2] Department of Internal Medicine, Södra Älvsborg Hospital, Borås, Sweden. ^[3] Medical Department, Capio St Göran Hospital, Stockholm, Sweden. ^[4] Department of Internal Medicine, Blekinge Hospital, Karlskrona, Sweden. ^[5] Department of Internal Medicine, Danderyd University Hospital, Stockholm, Sweden. ^[6] Janssen Cilag AB, Stockholm, Sweden. ^[7] Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden.;Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden. ^[8] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Department of Paediatrics, Örebro University Hospital, Örebro, Sweden.;Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK.;Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. ^[9] Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. ^[10]

关键词 Crohn’s disease clinical practice inflammatory bowel disease real-world data ustekinumab